ALNY: Alnylam Pharmaceuticals, Inc. Market Currents Page 3

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, February 9, 2012, 4:37 PM Alnylam Pharmaceuticals (ALNY): Q4 EPS of -$0.33 in-line. Revenue of $20.5M (-3.5% Y/Y) misses by $0.4M. (PR) Comment! [Earnings, Healthcare]
Thursday, January 19, 2012, 6:31 PM Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction in the size of its workforce, with the goal of focusing on drugs aimed at treating amyloidosis and hemophilia. Analysts estimate Alnylam's 2011 revenue fell 17%, and expect its 2012 revenue to decline another 26.3%. Shares are currently halted. Comment! [Healthcare, On the Move]
Wednesday, January 4, 2012, 9:52 AM Alynylam Pharmaceuticals (ALNY +3.3%) trades higher after the firm releases positive results from clinical tests of its cholesterol-reducing treatment. The firm says it will continue the study with increased dosages. Comment! [On the Move, Healthcare]
Friday, October 14, 2011, 2:29 PM Alnylam Pharmaceuticals (ALNY +4.5%) gains after Rodman & Renshaw initiates the shares at market outperform on valuation, saying it has a clear technological lead and strongest patent position in the RNAi space." Comment! [Healthcare, On the Move]
Tuesday, January 25, 2011, 12:15 PM Alnylam Pharma (ALNY +3.2%) gets a positive opinion for Orphan Drug Designation from European Medicines Agency for its ALN-TTR01, an RNAi therapeutic. (PR) Comment!
Wednesday, January 21, 2009, 3:29 PM Alnylam Pharmaceuticals (ALNY) +5.2%. A cream it's developing protected mice from herpes simplex 2, the virus that causes genital herpes - a potentially big step in protecting women from STDs. 1 Comment

ALNY Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals, Inc.